Context Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTX research report →
Range $4.5 – $6
Price Chart
About the company
Context Therapeutics Inc. , a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- CEO
- Martin A. Lehr
- IPO
- 2021
- Employees
- 15
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on CNTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.70M
- P/E
- -0.37
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- 0.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -96.54%
- ROIC
- -147.63%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-39,702,631
- Net Income
- $-36,123,615-35.2%
- EPS
- $-0.38+17.4%
- OCF Growth
- -81.3%
- FCF Growth
- +9.9%
- 52W High
- $3.62
- 52W Low
- $0.15
- 50D MA
- $0.27
- 200D MA
- $1.33
- Beta
- 1.77
- RSI (14)
- 34
- Avg Volume
- 1.43M
No earnings-call transcripts are available for CNTX yet.
- Free Float
- 69.4%
- Shares Outstanding
- 91.88M
- Float Shares
- 63.73M
of shares held by institutions
81 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nextech Invest Ltd. | 7.42M | 0 |
| Deep Track Capital, LP | 7.42M | 0 |
| Soleus Capital Management, L.P. | 7.06M | 0 |
| Blackrock, Inc. | 6.14M | ▼ 29.98K |
| Avidity Partners Management LP | 4.06M | ▼ 938.01K |
| Vanguard Group Inc | 3.79M | ▲ 290.88K |
| Vanguard Capital Management LLC | 3.43M | 0 |
| Aqr Capital Management LLC | 2.93M | ▲ 2.93M |
| Tcg Crossover Management, LLC | 2.68M | 0 |
| Acadian Asset Management LLC | 1.99M | ▲ 979.54K |
| Geode Capital Management, LLC | 1.90M | ▲ 65.16K |
| State Street Corp | 1.46M | ▲ 42.47K |
Held by 71 ETFs
Biggest fund positions in CNTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 24, 26 | Pasternak Andy | other | 45,000 |
| Jun 24, 26 | Stacey Jennifer Evans | other | 45,000 |
| Jun 24, 26 | West Linda | other | 45,000 |
| Jun 24, 26 | Smith Karen L. | other | 45,000 |
| Jun 24, 26 | Walker Luke Nathaniel | other | 45,000 |
| Jun 24, 26 | Kantoff Philip W. | other | 45,000 |
| Feb 19, 26 | Levit Alex C. | other | 270,000 |
| Feb 19, 26 | Minai-Azary Jennifer Lynn | other | 275,000 |
| Feb 19, 26 | Chagin Karen Deborah | other | 290,000 |
| Feb 19, 26 | Lehr Martin A. | other | 815,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNTX coverage
Recent articles, reports, and earnings notes.
No research on CNTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNTX report →Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
globenewswire.com · Nov 10
New Strong Sell Stocks for October 15th
zacks.com · Oct 15
New Strong Sell Stocks for October 13th
zacks.com · Oct 13
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
globenewswire.com · Sep 9
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
globenewswire.com · Aug 5
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 10
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
globenewswire.com · Jul 6
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
benzinga.com · Jun 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.